We advised the placement agents

Davis Polk advised the placement agents in connection with a private placement of $85 million of shares of common stock and pre-funded warrants of Korro Bio, Inc.

Korro intends to use the proceeds from the private placement, together with cash, cash equivalents and marketable securities, to advance its pipeline of potentially transformational therapies for genetic diseases being discovered by its novel RNA editing platform, with the remainder used for working capital and general corporate purposes.

Korro is a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases. Korro is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process, enabling a precise yet transient single base edit.

The Davis Polk capital markets team included partners Deanna L. Kirkpatrick and Yasin Keshvargar and associate Kerim K. Aksoy. All members of the Davis Polk team are based in the New York office.

Copy link to share post